The TIF procedure is a viable option due to the dramatic shift in the risk-reward profile associated with correcting the underlying anatomical failure and allows a majority of patients to stop taking daily medication for reflux.
Beverly Hills, CA (PRWEB) August 13, 2013
La Peer Health Systems announced new data from the Transoral Incisionless Fundoplication (TIF®) U.S. Registry presented at the 2013 SAGES annual meeting. Ali Mahtabifard, MD, provides the TIF procedure option to patients that suffer from gastroesophageal reflux disease (GERD) at the Reflux Surgery Center of Excellence.
According to the recent study, the TIF procedure was safe and effective in eliminating or improving a range of typical and atypical GERD symptoms, including heartburn and reflux, in up to 81% of patients. Also, in 81% of patients undergoing endoscopy 24-months after their TIF procedure, esophagitis was fully healed or notably improved.
“The TIF Registry data demonstrates the long-term value of a transoral anatomic correction in the treatment of GERD patients with mild to moderate disease,” said Dr. Mahtabifard. “The sustained response was seen by patients with either typical or atypical symptoms in this prospective multicenter registry of patients with chronic GERD.”
Twenty-four months after the EsophyX2® device was used in TIF procedures, more than two thirds of patients completely eliminated the need for daily proton pump inhibitor (PPIs) therapy. Symptom control achieved at six months remained stable over time, indicating durability of the TIF procedure.
“The TIF procedure is a viable option due to the dramatic shift in the risk-reward profile associated with correcting the underlying anatomical failure and allows a majority of patients to stop taking daily medication for reflux,” Dr. Mahtabifard said.
The risks associated with medical management of GERD patients for years or decades are becoming more evident. Traditional surgical interventions for GERD have historically been reserved for patients with the most severe disease. However, most patients have been unwilling to accept the well-documented side effects of difficulty swallowing and bloating associated with traditional surgery. In stark contrast, the TIF procedure offers an alternative option to select GERD patients because almost none of these side effects occurred in the TIF registry population.
The TIF procedure was also highlighted during these SAGES sessions:
- Reginald Bell, MD, of Swedish Medical Center, presented “Emerging Technologies and Techniques” during the Postgraduate Course Foregut Beyond GERD and Hiatal Hernia, Wednesday April 17
- Erik Wilson, MD, of Memorial Hermann Healthcare, presented “Transoral Incisionless Fundoplication (TIF), is the procedure here to stay?” during the Postgraduate Course Endoluminal Treatments – GERD and POEM, Thursday April 18
La Peer Health Systems is an outpatient surgery center in Beverly Hills, founded by doctors and focused on providing excellent patient care alongside the most cutting-edge medical treatments available. With 50 world-renowned physicians in 14 specialties, comprehensive medical treatment is offered that takes patients from consultation to diagnosis, treatment, surgery, and ultimately aftercare. The 14 medical departments include orthopedics & sports medicine, gastroenterology, head & neck surgery, colorectal & general surgery, podiatry, ophthalmology, pain management, plastics & reconstructive surgery, gynecology, spine surgery, interventional cardiology, bariatric surgery, thoracic surgery, and anesthesiology. Unlike large hospitals, La Peer's unique structure offers extremely personal care in a safe and controlled environment.
To learn more about La Peer Health Systems, visit http://www.lapeerhealth.com.
About EsophyX® and Transoral Incisionless Fundoplication (TIF®)
The EsophyX device was FDA cleared in 2007, and is commercially available in the United States. Inserted transorally with visual guidance from an endoscope, the EsophyX device is used in the TIF procedure to reconstruct the gastroesophageal valve (GEV), restoring its competency and reestablishing the barrier to reflux. TIF is a surgical solution that corrects the root cause of Gastroesophageal Reflux Disease (GERD)—a disease that affects over 60 million people in the U.S. The TIF procedure is based on traditional surgical principles is minimally invasive and offers similar effectiveness to a surgical repair with the safety profile of a transoral approach. To date, more than 10,000 patients have been treated worldwide. For more information, visit http://www.GERDHelp.com.
About EndoGastric Solutions®
EndoGastric Solutions, Inc. (http://www.endogastricsolutions.com), headquartered in Redwood City, California, is a leader in the endoluminal treatment of digestive diseases. EGS' mission is to utilize the most current wisdom in gastroenterology and surgery to develop procedures and products that address unmet needs in gastrointestinal diseases.